Form 8-K - Current report:
SEC Accession No. 0001140361-25-018697
Filing Date
2025-05-13
Accepted
2025-05-13 17:21:19
Documents
18
Period of Report
2025-05-12
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K ny20048472x3_8k.htm   iXBRL 8-K 37881
2 EXHIBIT 1.1 ny20048472x3_ex1-1.htm EX-1.1 209982
3 EXHIBIT 4.1 ny20048472x3_ex4-1.htm EX-4.1 85439
4 EXHIBIT 4.2 ny20048472x3_ex4-2.htm EX-4.2 116955
5 EXHIBIT 5.1 ny20048472x3_ex5-1.htm EX-5.1 19869
9 ny20048472x3_ex5-1logo01.jpg GRAPHIC 2769
  Complete submission text file 0001140361-25-018697.txt   729743

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA sgmo-20250512.xsd EX-101.SCH 3979
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE sgmo-20250512_lab.xml EX-101.LAB 21966
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE sgmo-20250512_pre.xml EX-101.PRE 16042
21 EXTRACTED XBRL INSTANCE DOCUMENT ny20048472x3_8k_htm.xml XML 4062
Mailing Address 501 CANAL BLVD. RICHMOND CA 94084
Business Address 501 CANAL BLVD. RICHMOND CA 94084 5109706000
SANGAMO THERAPEUTICS, INC (Filer) CIK: 0001001233 (see all company filings)

EIN.: 680359556 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-30171 | Film No.: 25941448
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)